

(51) International Patent Classification ⁵ : C07K 15/06, C12N 15/12 A61K 37/02	A1	(11) International Publication Number: WO 92/07004 (43) International Publication Date: 30 April 1992 (30.04.92)
(21) International Application Number: PCT/US91/07654 (22) International Filing Date: 18 October 1991 (18.10.91) (30) Priority data: 600,024 18 October 1990 (18.10.90) US (71) Applicant: CREATIVE BIOMOLECULES, INC. [US/ US]; 35 South Street, Hopkinton, MA 01748 (US). (72) Inventors: OZKAYNAK, Engin ; 44 Purdue Drive, Mil- ford, MA 01757 (US). OPPERMANN, Hermann ; 25 Summer Hill Road, Medway, MA 02053 (US). KUBER- ASAMPATH, Thangavel ; 6 Spring Street, Medway, MA 02053 (US). RUEGER, David, C. ; 150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US).		(74) Agent: PITCHER, Edmund, R.; Testa, Hurwitz & Thi- beault, Exchange Place, 53 State Street, Boston, MA 02109-2809 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro- pean patent), NL (European patent), SE (European pa- tent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: OSTEOGENIC PROTEIN (57) Abstract Disclosed are 1) the cDNA and amino acid sequence for a murine polypeptide chain, mOP-1, useful in dimeric osteogenic proteins, 2) methods of producing osteogenic proteins using recombinant technology, 3) methods of producing osteogenic devices comprising mOP-1 dispersed in xenogenic bone matrices, and 4) use of the osteogenic devices to mimic the natural course of endochondral bone formation in mammals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE ⁺	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

Osteogenic Protein

Background of the Invention

5

This invention relates to a novel polypeptide chain and to osteogenic proteins comprising this polypeptide chain which are capable of inducing osteogenesis in mammals, to a gene encoding the polypeptide chain, to
10 methods for its production using recombinant DNA techniques, and to bone and cartilage repair procedures using the osteogenic proteins.

Mammalian bone tissue is known to contain one or
15 more proteinaceous materials, presumably active during growth and natural bone healing, which can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the
20 literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

The developmental cascade of bone differentiation
25 consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

30

Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone

dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi, (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This
05 provides an experimental method for assaying protein extracts for their ability to induce endochondral bone in vivo. Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc.
10 Natl. Acad. Sci. USA 80:6591-6595).

The potential utility of these proteins has been recognized widely. It is contemplated that the availability of the protein would revolutionize orthopedic medicine, certain types of plastic surgery,
15 and various periodontal and craniofacial reconstructive procedures.

The observed properties of these protein fractions have induced an intense research effort in various laboratories directed to isolating and identifying the
20 pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from mammalian bone is disclosed by Sampath et al. (1987) Proc. Natl. Acad. Sci. USA 84: 7109-7113. Urist et al. (1984) Proc. Soc. Exp. Biol.
25 Med. 173: 194-199 disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride
30 and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

Urist et al. (1984) Proc. Natl. Acad. Sci. USA 81:
371-375 disclose a bovine bone morphogenetic protein
extract having the properties of an acidic polypeptide
and a molecular weight of approximately 18 kD. The
05 authors reported that the protein was present in a
fraction separated by hydroxyapatite chromatography,
and that it induced bone formation in mouse hindquarter
muscle and bone regeneration in trephine defects in rat
and dog skulls. Their method of obtaining the extract
10 from bone results in ill-defined and impure
preparations.

European Patent Application Serial No. 148,155,
published October 7, 1985, purports to disclose
osteogenic proteins derived from bovine, porcine, and
15 human origin. One of the proteins, designated by the
inventors as a P3 protein having a molecular weight of
22-24 kD, is said to have been purified to an
essentially homogeneous state. This material is
reported to induce bone formation when implanted into
20 animals.

International Application No. PCT/087/01537,
published January 14, 1988, discloses an impure
fraction from bovine bone which has bone induction
qualities. The named applicants also disclose putative
25 "bone inductive factors" produced by recombinant DNA
techniques. Four DNA sequences were retrieved from
human or bovine genomic or cDNA libraries and expressed
in recombinant host cells. While the applicants stated
that the expressed proteins may be bone morphogenic
30 proteins, bone induction was not demonstrated,
suggesting that the recombinant proteins are not
osteogenic. The same group reported subsequently

(Science 242:1528, Dec, 1988) that three of the four factors induce cartilage formation, and postulate that bone formation activity "is due to a mixture of regulatory molecules" and that "bone formation is most
05 likely controlled ... by the interaction of these molecules." Again, no bone induction was attributed to the products of expression of the cDNAs. See also Urist et al., EP0,212,474 entitled Bone Morphogenic Agents.

10 Wang et al. (1988) Proc. Nat. Acad. Sci. USA 85: 9484-9488 discloses the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a
15 molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been
20 determined.

Wang et al. (1990) Proc. Nat. Acad. Sci. USA 87: 2220-2227 describes the expression and partial purification of one of the cDNA sequences described in PCT 87/01537. Consistent cartilage and/or bone
25 formation with their protein requires a minimum of 600 ng of 50% pure material.

International Application No. PCT/89/04458 published April 19, 1990 (Int. Pub. No. WO90/003733), describes the purification and analysis of a family of
30 osteogenic factors called "P3 OF 31-34". The protein family contains at least four proteins, which are characterized by peptide fragment sequences. The

impure mixture P3 OF 31-34 is assayed for osteogenic activity. The activity of the individual proteins is neither assessed nor discussed.

It is an object of this invention to provide novel
05 polypeptide chains useful as subunits of dimeric
osteogenic proteins capable of endochondral bone
formation in allogenic and xenogenic implants in
mammals, including humans. Another object is to
provide genes encoding these polypeptide chains and to
10 provide methods for the production of osteogenic
proteins comprising these polypeptide chains using
recombinant DNA techniques, as well as to provide
antibodies capable of binding specifically to epitopes
on these proteins.

15 These and other objects and features of the
invention will be apparent from the description,
drawings, and claims which follow.

Summary of the Invention

This invention provides novel polypeptide chains
20 useful as either one or both subunits of dimeric
osteogenic proteins which, when implanted in a
mammalian body in association with a matrix, can induce
at the locus of the implant the full developmental
cascade of endochondral bone formation and bone marrow
25 differentiation.

A key to these developments was the elucidation of
amino acid sequence and structure data of native bovine
osteogenic protein. A protocol was developed which
results in retrieval of active, substantially pure
30 osteogenic protein from bovine bone having a half-

maximum bone forming activity of about 0.8 to 1.0 ng per mg of implant. The availability of the material enabled the inventors to elucidate key structural details of the protein necessary to achieve bone
05 formation. Knowledge of the protein's amino acid sequence and other structural features enabled the identification and cloning of native genes in the human genome.

Consensus DNA sequences based on partial sequence
10 data and observed homologies with regulatory proteins disclosed in the literature were used as probes for extracting genes encoding osteogenic protein from human genomic and cDNA libraries. One of the consensus sequences was used to isolate a previously unidentified
15 gene which, when expressed, encoded a protein comprising a region capable of inducing endochondral bone formation when properly modified, incorporated in a suitable matrix, and implanted as disclosed herein. The gene, called "hOP1" or "OP-1", is described in
20 greater detail in U.S. 660,162, filed 27-SEP-91 the disclosure of which is herein incorporated by reference.

Fragments of the hOP1 DNA sequence subsequently were used to probe a mouse embryo cDNA library in
25 search of additional genes encoding osteogenic proteins. This process isolated a heretofore unidentified DNA sequence which encodes a polypeptide chain referred to herein as mOP1 protein. Mouse OP1 (mOP-1) protein shares significant amino acid sequence
30 homology with human hOP1 protein, particularly in the region encoding the mature protein. Based on detailed structural and physical analyses of hOP1 protein and the high degree of amino acid sequence homology between

the hOP1 and mOP-1 proteins, homodimers of mOP1 proteins and heterodimers comprising mOP1 protein are believed to be capable of inducing endochondral bone formation, when the protein is dispersed in a suitable matrix, and implanted as disclosed herein.

The sequence of what is believed to be the mature form of the murine protein, designated herein mOP1-S, is (residues 292-430 of Seq. ID No. 1). The amino acid sequence of the full length protein, mOP1-PP (the "prepro" form, see infra), and the cDNA sequence encoding it are set forth in Seq. ID No. 1.

The invention provides recombinant dimeric proteins, and osteogenic devices comprising these proteins, wherein the subunits of the osteogenic dimers comprise an amino acid sequence described by Seq. ID No. 1, including allelic and biosynthetically mutated variants thereof.

Mouse OP1 can be expressed from intact or truncated cDNA or from synthetic DNAs in procaryotic or eucaryotic host cells, and then purified, cleaved, refolded, dimerized, and implanted in experimental animals. Currently preferred host cells include E. coli, or mammalian cells, such as CHO, COS or BSC cells. The osteogenic protein of the invention may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of native or biosynthetic protein, produced by expression of recombinant DNA in host cells.

Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries of various different species which encode appropriate amino acid sequences, or construct DNAs
05 from oligonucleotides, and then can express them in various types of host cells, including both procaryotes and eucaryotes, to produce large quantities of active proteins capable of inducing bone formation in mammals including humans.

10 In view of this disclosure, and using standard immunology techniques well known in the art, those skilled in the art also may raise polyclonal or monoclinal antibodies against all or part of the polypeptide chains described herein. Useful protocols
15 for antibody production may be found, for example, in Molecular Cloning-A Laboratory Manual (Sambrook et al., eds.) Cold Spring Harbor Press 2nd ed. 1989). See Book 3, Section 18.

The osteogenic proteins are useful in clinical
20 applications in conjunction with a suitable delivery or support system (matrix). The matrix is made up of particles of porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. The
25 particle size should be within the range of 70 - 850 mm, preferably 150mm - 420mm. It may be fabricated by close packing particulate material into a shape spanning the bone defect, or by otherwise structuring as desired a material that is biocompatible (non-
30 inflammatory) and, biodegradable in vivo to serve as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. Currently

preferred carriers include particulate, demineralized, guanidine extracted, species-specific (allogenic) bone, and specially treated particulate, protein extracted, demineralized, xenogenic bone. Optionally, such
05 xenogenic bone powder matrices also may be treated with proteases such as trypsin and/or fibril modifying agents to increase the intraparticle intrusion volume and surface area. Useful agents include solvents such as dichloromethane, trichloroacetic acid, acetonitrile
10 and acids such as trifluoroacetic acid and hydrogen fluoride. Alternatively, the matrix may be treated with a hot aqueous medium having a temperature within the range of about 37°C to 75°C, including heated acidic aqueous medium. Other potentially useful matrix
15 materials comprise collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates.

The osteogenic proteins and implantable osteogenic
20 devices enabled and disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1: 959-963). The
25 devices may be used to induce local endochondral bone formation in non-union fractures as demonstrated in animal tests, and in other clinical applications including dental and periodontal applications where bone formation is required. Another potential clinical
30 application is in cartilage repair, for example, in the treatment of osteoarthritis.

Brief Description of the Drawing

The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following
05 description, when read together with the accompanying drawings, in which:

FIGURE 1 compares the amino acid sequences of the mature hOP1 and mOP1 polypeptide chains: OP1-18 and mOP1-S.

10 Description

Purification protocols first were developed which enabled isolation of the osteogenic protein present in crude protein extracts from mammalian bone. (See PCT US 89/01453, and U.S. Serial No. 179,406 filed April 8,
15 1988, now U.S. Patent No. 4,968,950). The development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (bOP). bOP was characterized significantly; its ability to induce
20 cartilage and ultimately endochondral bone growth in cat, rabbit, and rat were demonstrated and studied; it was shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone
25 extracts. This dose dependent and highly specific activity was present whether or not the protein was glycosylated (see (1990) J. Biol. Chem. 265: 13198-13205). Sequence data obtained from the bovine materials suggested probe designs which were used to
30 isolate human genes. The OP human counterpart proteins have now been expressed and extensively characterized.

These discoveries enabled preparation of DNAs encoding totally novel, non-native protein constructs which individually as homodimers and combined with other species as heterodimers are capable of producing
05 true endochondral bone (see PCT WO 89/09788, published 19-OCT-89 and US Serial No. 315,342, filed 23-FEB-89, now U.S. Patent No. 5,011,691.) They also permitted expression of the natural material, truncated forms, muteins, analogs, fusion proteins, and various other
10 variants and constructs, from cDNAs and genomic DNAs retrieved from natural sources or from synthetic DNA produced using the techniques disclosed herein and using automated, commercially available equipment. The DNAs may be expressed using well established molecular
15 biology and recombinant DNA techniques in procaryotic or eucaryotic host cells, and may be oxidized and refolded in vitro if necessary, to produce biologically active protein.

One of the DNA sequences isolated from human
20 genomic and cDNA libraries encoded a previously unidentified gene, referred to herein as hOP1. The protein encoded by the isolated DNA was identified originally by amino acid homology with proteins in the TGF- β family. Consensus splice signals were found
25 where amino acid homologies ended, designating exon-intron boundaries. Three exons were combined to obtain a functional TGF- β like domain containing seven cysteines. (See, for example, U.S. Patent No. 5,011,691 or Ozkaynak, E. et al., (1990) EMBO. 9:
30 pp. 2085-2093). The DNA also is referred to in related applications as "OP1 and "OP-1".

In its native form, hOP1 expression yields an immature translation product ("hOP1-PP", where "PP" refers to "prepro form") of about 400 amino acids that subsequently is processed to yield a mature sequence of
05 139 amino acids ("OP1-18"). The active region (functional domain) of the protein comprises the C-terminal 97 amino acids of the hOP1 sequence, "OPS", which includes a conserved six cysteine skeleton. A longer active sequence is OP7, comprising the C-
10 terminal 102 amino acids, and which includes a conserved seven cysteine skeleton.

The full length cDNA sequence for hOP1, and its encoded "prepro" form hOP1-PP, which includes an N-terminal signal peptide sequence, are disclosed in
15 Seq. ID No. 3 (residues 1-431). The mature form of hOP1 protein expressed in mammalian cells, designated herein OP1-18, is indicated by residues 293-431 of Seq. ID No. 3.

cDNA sequences encoding the "prepro" form, of the
20 protein and the mature form, as well as various truncated forms of the gene, and fused genes, have been expressed in E. coli (see, for example, U.S. Serial No. 422, 699) and numerous mammalian cells (See, for example, PCT WO 91/05802, published 2-MAY-91, and all
25 have been shown to have osteogenic activity when implanted in a mammal in association with a suitable matrix.

Given the foregoing amino acid and DNA sequence information, various nucleic acids (RNAs and DNAs) can
30 be constructed which encode at least the active region of an OP1 protein (e.g., OPS or OP7, amino acid residues 335-431 or 330-431, respectively, of Seq. ID

No. 3) and various analogs thereof, as well as fusion proteins, truncated forms of the mature proteins, and similar constructs. Moreover, DNA hybridization probes can be constructed from fragments of the hOP1 DNA or
05 designed de novo based on the hOP1 DNA or amino acid sequence. These probes then can be used to screen different genomic and cDNA libraries to identify additional osteogenic proteins.

The DNAs can be produced by those skilled in the
10 art using well known DNA manipulation techniques involving genomic and cDNA isolation, construction of synthetic DNA from synthesized oligonucleotides, and cassette mutagenesis techniques. 15-100mer
oligonucleotides may be synthesized on a Biosearch DNA
15 Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer. The DNA may then be electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks
20 which may also be purified by PAGE.

DNAs for use as hybridization probes may be labelled (e.g., as with a radioisotope, by nick translation) and used to identify clones in a given library containing DNA to which the probe hybridizes,
25 following techniques well known in the art. The libraries may be obtained commercially or they may constructed de novo using conventional molecular biology techniques. Further information on DNA library construction and hybridization techniques can be found
30 in numerous texts known to those skilled in the art. See, for example, F.M. Ausubel, ed., Current Protocols in Molecular Biology-Vol. 1, (1989). In particular,

see unit 5, "Construction of Recombinant DNA Libraries" and Unit 6, "Screening of Recombinant Libraries."

Appropriately identified clones then can be sequenced using any of a number of techniques well known in the art. A DNA fragment containing the sequence of interest then can be subcloned into an expression vector and transfected into an appropriate host cell for protein expression and further characterization. The host may be a procaryotic or eucaryotic cell since the former's inability to glycosylate protein will not destroy the protein's osteogenic activity. Useful host cells include E. coli, Saccharomyces, the insect/baculovirus cell system, myeloma cells, and various mammalian cells. The vector additionally may encode various sequences to promote correct expression of the recombinant protein, including transcription promoter and termination sequences, enhancer sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred signal sequences for protein secretion, and the like. The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary structure formation. The recombinant osteogenic protein also may be expressed as a fusion protein. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium. All biologically active protein forms comprise dimeric species joined by disulfide bonds or otherwise associated, produced by oxidizing and refolding one or more of the various recombinant proteins within an appropriate eucaryotic cell or in vitro after expression of individual subunits. A detailed description of osteogenic protein

expressed from recombinant DNA in E. coli is disclosed in U.S. Serial No. 660,162, the disclosure of which has been incorporated by reference, supra. A detailed description of osteogenic protein expressed from
05 recombinant DNA in numerous different mammalian cells is disclosed in PCT WO 91/05802.

Exemplification

In an effort to identify additional DNA sequences encoding osteogenic proteins, a hybridization probe
10 specific to the C-terminus of the DNA of mature hOP1 was prepared using a StuI-EcoRI digest fragment of hOP1 (base pairs 1034-1354 in Seq. ID No. 3), and labelled with ^{32}P by nick translation, as described in the art. The C-terminus of the protein encodes a key functional
15 domain e.g., the "active region" for osteogenic activity. The C-terminus also is the region of the protein whose amino acid sequence shares specific amino acid sequence homology with particular proteins in the TGF- β super-family of regulatory proteins and which
20 includes the conserved cysteine skeleton.

Approximately 7×10^5 phages of an oligo (dT) primed 17.5 days p.c. mouse embryo 5' stretch cDNA (gt10) library (Clontech, Inc., Palo Alto, CA) was screened with the labelled probe. The screen was
25 performed using the following stringent hybridization conditions: 40% formamide, 5 x SSPE, 5 x Denhardt's solution, 0.1% SDS, at 37°C overnight, and washing in 0.1 x SSPE, 0.1% SDS, at 50°C.

Five recombinant phages were purified over three
30 rounds of screening. Phage DNA was prepared from all five phages, subjected to an EcoRI digest, subcloned

into the EcoR1 site of common pUC-type plasmid modified to allow single strand sequencing, and sequenced using means well known in the art.

Two different DNA sequences were identified by this
05 procedure. One DNA, referred to herein as mOP2, is described in detail in copending USSN 599,543, filed 18-Oct-90. A second DNA, referred to herein as mOP1, is described below.

The cDNA and encoded amino acid sequence for the
10 full length mOP1 protein is depicted in Seq. ID No. 1. The full-length form of the protein is referred to as the prepro form of mOP-1 ("mOP1-PP"), and includes a signal peptide sequence at its N-terminus. The amino acid sequence Ser-Ala-Leu-Ala-Asp (amino acid residues
15 26-30 in Seq. ID No. 1) is believed to constitute the cleavage site for the removal of the signal peptide sequence, leaving an intermediate form of the protein, the "pro" form, to be secreted from the expressing cell. The amino acid sequence Arg-Ser-Ile-Arg-Ser
20 (amino acid residue nos. 288-292 in Seq. ID No. 1) is believed to constitute the cleavage site that produces the mature form of the protein, herein referred to as "mOP1-S" and described by amino acid residues 292-430 of Seq. ID No. 1. The region of the mOP1 amino acid
25 sequence corresponding to the conserved six cysteine skeleton is described by residues 334-430 of Seq. ID No. 1. The region corresponding to the conserved seven cystein skeleton is described by residues 329-430 of Seq. ID No. 1.

30 Figure 1 compares the amino acid sequence homology of the mature hOP1 and mOP1 proteins (OP1-18 and mOP1-S). Amino acid identity is indicated by three

dots (...). As can be seen in Figure 1, the mature form of mOP1, mOP1-S shows significant sequence homology with OP-1-18 (98%), differing at only three positions in this region. Like OP-1-18, mOP1-S has a
05 seven cysteine functional domain (residues 38-139 of Fig. 1). The prepro form of the mOP1 protein shares substantially less amino acid sequence homology with that of OP1-PP. The high degree of homology of the mature domains is not surprising as the amino acid
10 sequences of the mature forms of TGF- β -like proteins generally also have been found to be highly conserved across different animal species (e.g., compare Vgr and Vgl, two related genes from mouse and Xenopus, respectively, see U.S. Pat. No. 5,011,691). The high
15 degree of amino acid sequence homology exhibited between the mature forms of the two animal species of OP1 proteins identified suggests that the mOP-1 protein will purify essentially as the human OP1 protein does, or with only minor modifications of the protocols
20 disclosed for human OP1 protein. Similarly, purified mOP1-S is predicted to have an apparent molecular weight of about 36 kD as a glycosylated oxidized homodimer, and about 18 kD as a reduced single subunit, as determined by comparison with molecular weight
25 standards on an SDS-polyacrylamide electrophoresis gel. There appear to be three potential N glycosylation sites in the mature mOP1 protein. The unglycosylated homodimer (e.g., one expressed from E. coli) is predicted to have a molecular weight of about 27 kD.

30

MATRIX PREPARATION

A. General Consideration of Matrix Properties

The currently preferred carrier material is a xenogenic bone-derived particulate matrix treated as disclosed herein. This carrier may be replaced by either a biodegradable-synthetic or synthetic-inorganic matrix (e.g., hydroxylapatite (HAP), collagen, tricalcium phosphate or polylactic acid, polyglycolic acid and various copolymers thereof.)

Studies have shown that surface charge, particle size, the presence of mineral, and the methodology for combining matrix and osteogenic protein all play a role in achieving successful bone induction. Perturbation of the charge by chemical modification abolishes the inductive response. Particle size influences the quantitative response of new bone; particles between 75 μm and 420 μm elicit the maximum response. Contamination of the matrix with bone mineral will inhibit bone formation. Most importantly, the procedures used to formulate OP onto the matrix are extremely sensitive to the physical and chemical state of both the osteogenic protein and the matrix.

The sequential cellular reactions in the interface of the bone matrix/osteogenic protein implants are complex. The multistep cascade includes: binding of fibrin and fibronectin to implanted matrix, chemotaxis of cells, proliferation of fibroblasts, differentiation into chondroblasts, cartilage formation, vascular invasion, bone formation, remodeling, and bone marrow differentiation.

A successful carrier for osteogenic protein must perform several important functions. It must bind osteogenic protein and act as a slow release delivery system, accommodate each step of the cellular response

during bone development, and protect the osteogenic protein from nonspecific proteolysis. In addition, selected materials must be biocompatible in vivo and preferably biodegradable; the carrier must act as a temporary scaffold until replaced completely by new bone. Polylactic acid (PLA), polyglycolic acid (PGA), and various combinations have different dissolution rates in vivo. In bones, the dissolution rates can vary according to whether the implant is placed in cortical or trabecular bone.

Matrix geometry, particle size, the presence of surface charge, and the degree of both intra-and-inter-particle porosity are all important to successful matrix performance. It is preferred to shape the matrix to the desired form of the new bone and to have dimensions which span non-union defects. Rat studies show that the new bone is formed essentially having the dimensions of the device implanted.

The matrix may comprise a shape-retaining solid made of loosely adhered particulate material, e.g., with collagen. It may also comprise a molded, porous solid, or simply an aggregation of close-packed particles held in place by surrounding tissue. Masticated muscle or other tissue may also be used. Large allogenic bone implants can act as a carrier for the matrix if their marrow cavities are cleaned and packed with particle and the dispersed osteogenic protein.

The preferred matrix material, prepared from xenogenic bone and treated as disclosed herein, produces an implantable material useful in a variety of clinical settings. In addition to its use as a matrix

for bone formation in various orthopedic, periodontal, and reconstructive procedures, the matrix also may be used as a sustained release carrier, or as a collagenous coating for implants. The matrix may be
05 shaped as desired in anticipation of surgery or shaped by the physician or technician during surgery. Thus, the material may be used for topical, subcutaneous, intraperitoneal, or intramuscular implants; it may be shaped to span a nonunion fracture or to fill a bone
10 defect. In bone formation or conduction procedures, the material is slowly absorbed by the body and is replaced by bone in the shape of or very nearly the shape of the implant.

Various growth factors, hormones, enzymes,
15 therapeutic compositions, antibiotics, and other body treating agents also may be absorbed onto the carrier material and will be released over time when implanted as the matrix material is slowly absorbed. Thus, various known growth factors such as EGF, PDGF, IGF,
20 FGF, TGF- α , and TGF- β may be released in vivo. The material can be used to release chemotherapeutic agents, insulin, enzymes, or enzyme inhibitors.

B. Bone-Derived Matrices

1. Preparation of Demineralized Bone

25 Demineralized bone matrix, preferably bovine bone matrix, is prepared by previously published procedures (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595). Bovine diaphyseal bones (age 1-10 days) are obtained from a local slaughterhouse and
30 used fresh. The bones are stripped of muscle and fat,

cleaned of periosteum, demarrowed by pressure with cold water, dipped in cold absolute ethanol, and stored at -20°C. They are then dried and fragmented by crushing and pulverized in a large mill. Care is taken to
05 prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size in the range of 70-850 μm , preferably 150-420 μm , and is defatted by two washes of approximately two hours duration with three volumes of chloroform and methanol
10 (3:1). The particulate bone is then washed with one volume of absolute ethanol and dried over one volume of anhydrous ether yielding defatted bone powder. The defatted bone powder is then demineralized by four successive treatments with 10 volumes of 0.5 N HCl at
15 4°C for 40 min. Finally, neutralizing washes are done on the demineralized bone powder with a large volume of water.

2. Guanidine Extraction

Demineralized bone matrix thus prepared is
20 extracted with 5 volumes of 4 M guanidine-HCl, 50mM Tris-HCl, pH 7.0 for 16 hr. at 4°C. The suspension is filtered. The insoluble material is collected and used to fabricate the matrix. The material is mostly collagenous in nature. It is devoid of osteogenic or
25 chondrogenic activity.

3. Matrix Treatments

The major component of all bone matrices is Type-I collagen. In addition to collagen, demineralized bone extracted as disclosed above
30 includes non-collagenous proteins which may account for 5% of its mass. In a xenogenic matrix, these

noncollagenous components may present themselves as potent antigens, and may constitute immunogenic and/or inhibitory components. These components also may inhibit osteogenesis in allogenic implants by
05 interfering with the developmental cascade of bone differentiation. It has been discovered that treatment of the matrix particles with a collagen fibril-modifying agent extracts potentially unwanted components from the matrix, and alters the surface
10 structure of the matrix material. Useful agents include acids, organic solvents or heated aqueous media. Various treatments are described below. A detailed physical analysis of the effect these fibril-modifying agents have on demineralized, guanidine-
15 extracted bone collagen particles is disclosed in copending U.S. Patent Application Serial No. 483,913, filed February 22, 1990.

After contact with the fibril-modifying agent, the treated matrix is washed to remove any extracted
20 components, following a form of the procedure set forth below:

1. Suspend in TBS (Tris-buffered saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) or water and
25 stir at room temperature (RT) for 30 minutes (sufficient time to neutralize the pH);

2. Centrifuge and repeat wash step; and

3. Centrifuge; discard supernatant; water wash residue; and then lyophilize.

30 3.1 Acid Treatments

1. Trifluoroacetic acid.

Trifluoroacetic acid is a strong non-oxidizing acid that is a known swelling agent for proteins, and which modifies collagen fibrils.

05 Bovine bone residue prepared as described
above is sieved, and particles of the appropriate size
are collected. These particles are extracted with
various percentages (1.0% to 100%) of trifluoroacetic
acid and water (v/v) at 0°C or room temperature for 1-2
10 hours with constant stirring. The treated matrix is
filtered, lyophilized, or washed with water/salt and
then lyophilized.

2. Hydrogen Fluoride.

 Like trifluoroacetic acid, hydrogen fluoride
15 is a strong acid and swelling agent, and also is
capable of altering intraparticle surface structure.
Hydrogen fluoride is also a known deglycosylating
agent. As such, HF may function to increase the
osteogenic activity of these matrices by removing the
20 antigenic carbohydrate content of any glycoproteins
still associated with the matrix after guanidine
extraction.

 Bovine bone residue prepared as described above is
sieved, and particles of the appropriate size are
25 collected. The sample is dried in vacuo over P_2O_5 ,
transferred to the reaction vessel and exposed to
anhydrous hydrogen fluoride (10-20 ml/g of matrix) by
distillation onto the sample at -70°C. The vessel is
allowed to warm to 0°C and the reaction mixture is

stirred at this temperature for 120 minutes. After evaporation of the hydrogen fluoride in vacuo, the residue is dried thoroughly in vacuo over KOH pellets to remove any remaining traces of acid. Extent of
05 deglycosylation can be determined from carbohydrate analysis of matrix samples taken before and after treatment with hydrogen fluoride, after washing the samples appropriately to remove non-covalently bound carbohydrates. SDS-extracted protein from HF-treated
10 material is negative for carbohydrate as determined by Con A blotting.

The deglycosylated bone matrix is next washed twice in TBS (Tris-buffered saline) or UTBS, water-washed, and then lyophilized.

15 Other acid treatments are envisioned in addition to HF and TFA. TFA is a currently preferred acidifying reagent in these treatments because of its volatility. However, it is understood that other, potentially less caustic acids may be used, such as
20 acetic or formic acid.

3.2 Solvent Treatment

1. Dichloromethane.

Dichloromethane (DCM) is an organic solvent capable of denaturing proteins without affecting their
25 primary structure. This swelling agent is a common reagent in automated peptide synthesis, and is used in washing steps to remove components.

Bovine bone residue, prepared as described above, is sieved, and particles of the appropriate size

are incubated in 100% DCM or, preferably, 99.9% DCM/0.1% TFA. The matrix is incubated with the swelling agent for one or two hours at 0°C or at room temperature. Alternatively, the matrix is treated with
05 the agent at least three times with short washes (20 minutes each) with no incubation.

2. Acetonitrile.

Acetonitrile (ACN) is an organic solvent, capable of denaturing proteins without affecting their
10 primary structure. It is a common reagent used in high-performance liquid chromatography, and is used to elute proteins from silica-based columns by perturbing hydrophobic interactions.

Bovine bone residue particles of the
15 appropriate size, prepared as described above, are treated with 100% ACN (1.0 g/30 ml) or, preferably, 99.9% ACN/0.1% TFA at room temperature for 1-2 hours with constant stirring. The treated matrix is then water-washed, or washed with urea buffer, or 4 M NaCl
20 and lyophilized. Alternatively, the ACN or ACN/TFA treated matrix may be lyophilized without wash.

3. Isopropanol.

Isopropanol is also an organic solvent capable of denaturing proteins without affecting their primary
25 structure. It is a common reagent used to elute proteins from silica HPLC columns.

Bovine bone residue particles of the appropriate size prepared as described above are treated with 100% isopropanol (1.0 g/30 ml) or,

preferably, in the presence of 0.1% TFA, at room temperature for 1-2 hours with constant stirring. The matrix is then water-washed or washed with urea buffer or 4 M NaCl before being lyophilized.

05 4. Chloroform

Chloroform also may be used to increase surface area of bone matrix like the reagents set forth above, either alone or acidified.

Treatment as set forth above is effective to
10 assure that the material is free of pathogens prior to implantation.

3.3 Heat Treatment

The currently most preferred agent is a heated aqueous fibril-modifying medium such as water, to
15 increase the matrix particle surface area and porosity. The currently most preferred aqueous medium is an acidic aqueous medium having a pH of less than about 4.5, e.g., within the range of pH 2 - pH 4. which may help to "swell" the collagen before heating. 0.1%
20 acetic acid, which has a pH of about 3, currently is preferred. 0.1 M acetic acid also may be used.

Various amounts of delipidated, demineralized guanidine-extracted bone collagen are heated in the aqueous medium (1g matrix/30ml aqueous medium) under
25 constant stirring in a water jacketed glass flask, and maintained at a given temperature for a predetermined period of time. Preferred treatment times are about one hour, although exposure times of between about 0.5 to two hours appear acceptable. The temperature

employed is held constant at a temperature within the range of about 37°C to 75°C. The currently preferred heat treatment temperature is within the range of 45°C to 60°C.

05 After the heat treatment, the matrix is filtered, washed, lyophilized and used for implant. Where an acidic aqueous medium is used, the matrix also is preferably neutralized prior to washing and lyophilization. A currently preferred neutralization
10 buffer is a 200mM sodium phosphate buffer, pH 7.0. To neutralize the matrix, the matrix preferably first is allowed to cool following thermal treatment, the acidic aqueous medium (e.g., 0.1% acetic acid) then is removed and replaced with the neutralization buffer and the
15 matrix agitated for about 30 minutes. The neutralization buffer then may be removed and the matrix washed and lyophilized (see infra).

 The matrix also may be treated to remove contaminating heavy metals, such as by exposing the
20 matrix to a metal ion chelator. For example, following thermal treatment with 0.1% acetic acid, the matrix may be neutralized in a neutralization buffer containing EDTA (sodium ethylenediaminetetraacetic acid), e.g., 200 mM sodium phosphate, 5mM EDTA, pH 7.0. 5 mM EDTA
25 provides about a 100-fold molar excess of chelator to residual heavy metals present in the most contaminated matrix tested to date. Subsequent washing of the matrix following neutralization appears to remove the bulk of the EDTA. EDTA treatment of matrix particles
30 reduces the residual heavy metal content of all metals tested (Sb, As, Be, Cd, Cr, Cu, Co, Pb, Hg, Ni, Se, Ag, Zn, Tl) to less than about 1 ppm. Bioassays with EDTA-

treated matrices indicate that treatment with the metal ion chelator does not inhibit bone inducing activity.

The collagen matrix materials preferably take the form of a fine powder, insoluble in water, comprising nonadherent particles. It may be used simply by packing into the volume where new bone growth or sustained release is desired, held in place by surrounding tissue. Alternatively, the powder may be encapsulated in, e.g., a gelatin or polylactic acid coating, which is adsorbed readily by the body. The powder may be shaped to a volume of given dimensions and held in that shape by interadhering the particles using, for example, soluble, species-biocompatible collagen. The material may also be produced in sheet, rod, bead, or other macroscopic shapes.

FABRICATION OF OSTEOGENIC DEVICE

The naturally sourced and recombinant protein as set forth above, and other constructs, can be combined and dispersed in a suitable matrix preparation using any of the methods described below. In general, 50-100 ng of active protein is combined with the inactive carrier matrix (e.g., 25 mg for rat bioassays). Greater amounts may be used for large implants.

1. Ethanol Precipitation

Matrix is added to osteogenic protein dissolved in guanidine-HCl. Samples are vortexed and incubated at a low temperature (e.g., 4°C). Samples are then further vortexed. Cold absolute ethanol (5 volumes) is added to the mixture which is then stirred

and incubated, preferably for 30 minutes at -20°C. After centrifugation (microfuge, high speed) the supernatant is discarded. The reconstituted matrix is washed twice with cold concentrated ethanol in water
05 (85% EtOH) and then lyophilized.

2. Acetonitrile Trifluoroacetic Acid Lyophilization

In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution is
10 added to the carrier material. Samples are vigorously vortexed many times and then lyophilized. This method is currently preferred, and has been tested with osteogenic protein at varying concentrations and different levels of purity.

15 3. Urea Lyophilization

For those osteogenic proteins that are prepared in urea buffer, the protein is mixed with the matrix material, vortexed many times, and then lyophilized. The lyophilized material may be used "as
20 is" for implants.

4. Buffered Saline Lyophilization

CP1 preparations in physiological saline may also be vortexed with the matrix and lyophilized to produce osteogenically active material.

25 These procedures also can be used to adsorb other active therapeutic drugs, hormones, and various bioactive species to the matrix for sustained release purposes.

BIOASSAY

The functioning of the various proteins and devices of this invention can be evaluated with an in vivo bioassay. Studies in rats show the osteogenic effect in an appropriate matrix to be dependent on the dose of osteogenic protein dispersed in the matrix. No activity is observed if the matrix is implanted alone. In vivo bioassays performed in the rat model also have shown that demineralized, guanidine-extracted xenogenic bone matrix materials of the type described in the literature are ineffective as a carrier, fail to induce bone, and produce an inflammatory and immunological response when implanted unless treated as disclosed above. In certain species (e.g., monkey) allogenic matrix materials also apparently are ineffective as carriers. The following sets forth various procedures for preparing osteogenic devices from the proteins and matrix materials prepared as set forth above, and for evaluating their osteogenic utility.

20 A. Rat Model

1. Implantation

The bioassay for bone induction as described by Sampath and Reddi ((1983) Proc. Natl. Acad. Sci. USA 80 6591-6595), herein incorporated by reference, may be used to monitor endochondral bone differentiation activity. This assay consists of implanting test samples in subcutaneous sites in recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic

region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is
05 designated as day one of the experiment. Implants were removed on day 12. The heterotrophic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotropic sites. As disclosed herein, both allogenic (rat bone
10 matrix) and xenogenic (bovine bone matrix) implants were assayed.

2. Cellular Events

Successful implants exhibit a controlled progression through the stages of protein-induced
15 endochondral bone development, including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on
20 day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to
25 eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

3. Histological Evaluation

30 Histological sectioning and staining is preferred to determine the extent of osteogenesis in

the implants. Implants are fixed in Bouins Solution, embedded in paraffin, and cut into 6-8 μ m sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of endochondral bone. Twelve day implants are usually sufficient to determine whether the implants contain newly induced bone.

4. Biological Markers

Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be determined spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation quickly after the implants are removed from the rat. Alternatively, the amount of bone formation can be determined by measuring the calcium content of the implant.

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 05 (i) APPLICANT:
 OZKAYNAK, ENGIN
 OPPERMANN, HERMANN
 KUBERASAMPATH, THANGAVEL
 RUEGER, DAVID C.
- (ii) TITLE OF INVENTION: OSTEOGENIC DEVICES
- (iii) NUMBER OF SEQUENCES: 4
- 10 (iv) CORRESPONDENCE ADDRESS:
 (A) ADDRESSEE: TESTA, HURWITZ & THIBEAULT
 (B) STREET: 53 STATE STREET
 (C) CITY: BOSTON
 (D) STATE: MASSACHUSETTS
15 (E) COUNTRY: U.S.A.
 (F) ZIP: 02109
- (v) COMPUTER READABLE FORM:
 (A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
10 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: Patent In Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 (A) APPLICATION NUMBER:
 (B) FILING DATE:
25 (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 (A) NAME: PITCHER, EDMUND R.
 (B) REGISTRATION NUMBER: 27,829
 (C) REFERENCE/DOCKET NUMBER: CRP-001PC5
- 30 (ix) TELECOMMUNICATION INFORMATION:
 (A) TELEPHONE: 617/248-7000
 (B) TELEFAX: 617/248-7100

(2) INFORMATION FOR SEQ ID NO:1:

- 35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1873 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: MURIDAE
 (F) TISSUE TYPE: EMBRYO

05 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 104..1393
 (D) OTHER INFORMATION: /function= "OSTEOGENIC PROTEIN"
 /product= "mOP1-PP"
 /note= "mOP1 (CDNA)"

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	CTGCAGCAAG TGACCTCGGG TCGTGGACCG CTGCCCTGCC CCCTCCGCTG CCACCTGGGG	60
	CGGCGCGGGC CCGGTGCCCC GGATCGCGCG TAGAGCCGGC GCG ATG CAC GTG CGC	115
	Met His Val Arg	
	1	
15	TCG CTG CGC GCT GCG GCG CCA CAC AGC TTC GTG GCG CTC TGG GCG CCT	163
	Ser Leu Arg Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro	
	5 10 15 20	
	CTG TTC TTG CTG CGC TCC GCC CTG GCC GAT TTC AGC CTG GAC AAC GAG	211
	Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn Glu	
20	25 30 35	
	GTG CAC TCC AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG	259
	Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg Arg	
	40 45 50	
	GAG ATG CAG CGG GAG ATC CTG TCC ATC TTA GGG TTG CCC CAT CGC CCG	307
25	Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg Pro	
	55 60 65	
	CGC CCG CAC CTC CAG GGA AAG CAT AAT TCG GCG CCC ATG TTC ATG TTG	355
	Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met Leu	
	70 75 80	
30	GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG AGC GGG CCG GAC GGA CAG	403
	Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Ser Gly Pro Asp Gly Gln	
	85 90 95 100	
	GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC CCC CCT	451
	Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly Pro Pro	
35	105 110 115	
	TTA GCC AGC CTG CAG GAC AGC CAT TTC CTC ACT GAC GCC GAC ATG GTC	499
	Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp Met Val	
	120 125 130	
	ATG AGC TTC GTC AAC CTA GTG GAA CAT GAC AAA GAA TTC TTC CAC CCT	547

	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys	Glu	Phe	Phe	His	Pro	
			135					140					145				
05	CGA	TAC	CAC	CAT	CGG	GAG	TTC	CGG	TTT	GAT	CTT	TCC	AAG	ATC	CCC	GAG	595
	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu	Ser	Lys	Ile	Pro	Glu	
		150					155					160					
	GGC	GAA	GCG	GTG	ACC	GCA	GCC	GAA	TTC	AGG	ATC	TAT	AAG	GAC	TAC	ATC	643
	Gly	Glu	Ala	Val	Thr	Ala	Ala	Glu	Phe	Arg	Ile	Tyr	Lys	Asp	Tyr	Ile	
		165				170					175					180	
10	CGG	GAG	CGA	TTT	GAC	AAC	GAG	ACC	TTC	CAG	ATC	ACA	GTC	TAT	CAG	TGG	691
	Arg	Glu	Arg	Phe	Asp	Asn	Glu	Thr	Phe	Gln	Ile	Thr	Val	Tyr	Gln	Trp	
					185					190					195		
	CTC	CAG	GAG	CAC	TCA	GGC	AGG	GAG	TCG	GAC	CTC	TTC	TTG	CTG	GAC	AGC	739
	Leu	Gln	Glu	His	Ser	Gly	Arg	Glu	Ser	Asp	Leu	Phe	Leu	Leu	Asp	Ser	
				200					205					210			
15	CGC	ACC	ATC	TGG	GCT	TCT	GAG	GAG	GGC	TGG	TTG	GTG	TTT	GAT	ATC	ACA	787
	Arg	Thr	Ile	Trp	Ala	Ser	Glu	Glu	Gly	Trp	Leu	Val	Phe	Asp	Ile	Thr	
			215					220					225				
20	GCC	ACC	AGC	AAC	CAC	TGG	GTG	GTC	AAC	CCT	CGG	CAC	AAC	CTG	GGC	TTA	835
	Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg	His	Asn	Leu	Gly	Leu	
		230					235					240					
	CAG	CTC	TCT	GTG	GAG	ACC	CTG	GAT	GGG	CAG	AGC	ATC	AAC	CCC	AAG	TTG	883
	Gln	Leu	Ser	Val	Glu	Thr	Leu	Asp	Gly	Gln	Ser	Ile	Asn	Pro	Lys	Leu	
		245				250					255					260	
25	GCA	GGC	CTG	ATT	GGA	CGG	CAT	GGA	CCC	CAG	AAC	AAG	CAA	CCC	TTC	ATG	931
	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn	Lys	Gln	Pro	Phe	Met	
					265					270					275		
	GTG	GCC	TTC	TTC	AAG	GCC	ACG	GAA	GTC	CAT	CTC	CGT	AGT	ATC	CGG	TCC	979
	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Leu	Arg	Ser	Ile	Arg	Ser	
				280					285					290			
30	ACG	GGG	GGC	AAG	CAG	CGC	AGC	CAG	AAT	CGC	TCC	AAG	ACG	CCA	AAG	AAC	1027
	Thr	Gly	Gly	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser	Lys	Thr	Pro	Lys	Asn	
			295					300					305				
35	CAA	GAG	GCC	CTG	AGG	ATG	GCC	AGT	GTG	GCA	GAA	AAC	AGC	AGC	AGT	GAC	1075
	Gln	Glu	Ala	Leu	Arg	Met	Ala	Ser	Val	Ala	Glu	Asn	Ser	Ser	Ser	Asp	
		310					315					320					
	CAG	AGG	CAG	GCC	TGC	AAG	AAA	CAT	GAG	CTG	TAC	GTC	AGC	TTC	CGA	GAC	1123
	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val	Ser	Phe	Arg	Asp	
		325				330					335					340	
40	CTT	GGC	TGG	CAG	GAC	TGG	ATC	ATT	GCA	CCT	GAA	GGC	TAT	GCT	GCC	TAC	1171
	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala	Ala	Tyr	

	345	350	355	
	TAC TGT GAG GGA GAG TGC GCC TTC CCT CTG AAC TCC TAC ATG AAC GCC			1219
	Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn Ala			
	360	365	370	
05	ACC AAC CAC GCC ATC GTC CAG ACA CTG GTT CAC TTC ATC AAC CCA GAC			1267
	Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro Asp			
	375	380	385	
	ACA GTA CCC AAG CCC TGC TGT GCG CCC ACC CAG CTC AAC GCC ATC TCT			1315
	Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser			
10	390	395	400	
	GTC CTC TAC TTC GAC GAC AGC TCT AAT GTC GAC CTG AAG AAG TAC AGA			1363
	Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Asp Leu Lys Lys Tyr Arg			
	405	410	415	420
	AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCTTCC TGAGACCCTG			1413
15	Asn Met Val Val Arg Ala Cys Gly Cys His			
	425	430		
	ACCTTTGCGG GGCCACACCT TTCCAAATCT TCGATGTCTC ACCATCTAAG TCTCTCACTG			1473
	CCCACCTTGG CGAGGAGAAC AGACCAACCT CTCCTGAGCC TTCCCTCACC TCCCAACCGG			1533
	AAGCATGTAA GGGTTCCAGA AACCTGAGCG TGCAGCAGCT GATGAGCGCC CTTTCCTTCT			1593
20	GGCACGTGAC GGACAAGATC CTACCAGCTA CCACAGCAAA CGCCTAAGAG CAGGAAAAAT			1653
	GTCTGCCAGG AAAGTGTCCA GTGTCCACAT GGCCCCTGGC GCTCTGAGTC TTTGAGGAGT			1713
	AATCGCAAGC CTCGTTTCAGC TGCAGCAGAA GGAAGGGCTT AGCCAGGGTG GGCGCTGGCG			1773
	TCTGTGTTGA AGGGAAACCA AGCAGAAGCC ACTGTAATGA TATGTCACAA TAAAACCCAT			1833
	GAATGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGAATTC			1873

25 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 430 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (D) OTHER INFORMATION: /product= "mOP1-PP"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

	Met	His	Val	Arg	Ser	Leu	Arg	Ala	Ala	Ala	Pro	His	Ser	Phe	Val	Ala	
	1				5					10					15		
	Leu	Trp	Ala	Pro	Leu	Phe	Leu	Leu	Arg	Ser	Ala	Leu	Ala	Asp	Phe	Ser	
				20					25					30			
05	Leu	Asp	Asn	Glu	Val	His	Ser	Ser	Phe	Ile	His	Arg	Arg	Leu	Arg	Ser	
		35						40				45					
	Gln	Glu	Arg	Arg	Glu	Met	Gln	Arg	Glu	Ile	Leu	Ser	Ile	Leu	Gly	Leu	
		50					55					60					
10	Pro	His	Arg	Pro	Arg	Pro	His	Leu	Gln	Gly	Lys	His	Asn	Ser	Ala	Pro	
	65					70					75					80	
	Met	Phe	Met	Leu	Asp	Leu	Tyr	Asn	Ala	Met	Ala	Val	Glu	Glu	Ser	Gly	
					85					90					95		
	Pro	Asp	Gly	Gln	Gly	Phe	Ser	Tyr	Pro	Tyr	Lys	Ala	Val	Phe	Ser	Thr	
				100			105							110			
15	Gln	Gly	Pro	Pro	Leu	Ala	Ser	Leu	Gln	Asp	Ser	His	Phe	Leu	Thr	Asp	
			115					120					125				
	Ala	Asp	Met	Val	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys	Glu	
		130					135					140					
20	Phe	Phe	His	Pro	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu	Ser	
	145					150					155				160		
	Lys	Ile	Pro	Glu	Gly	Glu	Ala	Val	Thr	Ala	Ala	Glu	Phe	Arg	Ile	Tyr	
					165					170					175		
	Lys	Asp	Tyr	Ile	Arg	Glu	Arg	Phe	Asp	Asn	Glu	Thr	Phe	Gln	Ile	Thr	
			180					185						190			
25	Val	Tyr	Gln	Trp	Leu	Gln	Glu	His	Ser	Gly	Arg	Glu	Ser	Asp	Leu	Phe	
			195					200					205				
	Leu	Leu	Asp	Ser	Arg	Thr	Ile	Trp	Ala	Ser	Glu	Glu	Gly	Trp	Leu	Val	
		210					215				220						
30	Phe	Asp	Ile	Thr	Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg	His	
	225					230					235					240	
	Asn	Leu	Gly	Leu	Gln	Leu	Ser	Val	Glu	Thr	Leu	Asp	Gly	Gln	Ser	Ile	
					245					250					255		
	Asn	Pro	Lys	Leu	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn	Lys	
			260						265					270			
35	Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Leu	Arg	
		275					280						285				

/standard_name= "hOP1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

05	GGTGCGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG CCGGCGCG ATG CAC GTG	57
	Met His Val	
	1	
	CGC TCA CTG CGA GCT GCG GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA	105
	Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala	
	5 10 15	
10	CCC CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC AGC CTG GAC AAC	153
	Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn	
	20 25 30 35	
	GAG GTG CAC TCG AGC TTC ATC CAC CGG CGC CTC CGC AGC CAG GAG CGG	201
	Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg	
	40 45 50	
15	CGG GAG ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG CCC CAC CGC	249
	Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg	
	55 60 65	
	CCG CGC CCG CAC CTC CAG GGC AAG CAC AAC TCG GCA CCC ATG TTC ATG	297
	Pro Arg Pro His Leu Gln Lys Lys His Asn Ser Ala Pro Met Phe Met	
20	70 75 80	
	CTG GAC CTG TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG CCC GGC	345
	Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly	
	85 90 95	
25	GGC CAG GGC TTC TCC TAC CCC TAC AAG GCC GTC TTC AGT ACC CAG GGC	393
	Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly	
	100 105 110 115	
	CCC CCT CTG GCC AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC GAC	441
	Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp	
	120 125 130	
30	ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA CAT GAC AAG GAA TTC TTC	489
	Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe	
	135 140 145	
	CAC CCA CGC TAC CAC CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC	537
	His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile	
35	150 155 160	
	CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC CGG ATC TAC AAG GAC	585
	Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp	
	165 170 175	
	TAC ATC CGG GAA CGC TTC GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT	633

	Tyr 180	Ile	Arg	Glu	Arg	Phe 185	Asp	Asn	Glu	Thr	Phe 190	Arg	Ile	Ser	Val	Tyr 195	
05	CAG Gln	GTG Val	CTC Leu	CAG Gln	GAG Glu	CAC His	TTG Leu	GGC Gly	AGG Arg	GAA Glu	TCG Ser	GAT Asp	CTC Leu	TTC Phe	CTG Leu	CTC Leu	681
					200					205					210		
	GAC Asp	AGC Ser	CGT Arg	ACC Thr	CTC Leu	TGG Trp	GCC Ala	TCG Ser	GAG Glu	GAG Glu	GGC Gly	TGG Trp	CTG Leu	GTG Val	TTT Phe	GAC Asp	729
				215					220					225			
10	ATC Ile	ACA Thr	GCC Ala	ACC Thr	AGC Ser	AAC Asn	CAC His	TGG Trp	GTG Val	GTC Val	AAT Asn	CCG Pro	CGG Arg	CAC His	AAC Asn	CTG Leu	777
				230				235					240				
	GGC Gly	CTG Leu	CAG Gln	CTC Leu	TCG Ser	GTG Val	GAG Glu	ACG Thr	CTG Leu	GAT Asp	GGG Gly	CAG Gln	AGC Ser	ATC Ile	AAC Asn	CCC Pro	825
		245					250					255					
15	AAG Lys	TTG Leu	GCG Ala	GGC Gly	CTG Leu	ATT Ile	GGG Gly	CGG Arg	CAC His	GGG Gly	CCC Pro	CAG Gln	AAC Asn	AAG Lys	CAG Gln	CCC Pro	873
	260					265					270					275	
20	TTC Phe	ATG Met	GTG Val	GCT Ala	TTC Phe	TTC Phe	AAG Lys	GCC Ala	ACG Thr	GAG Glu	GTC Val	CAC His	TTC Phe	CGC Arg	AGC Ser	ATC Ile	921
					280					285					290		
	CGG Arg	TCC Ser	ACG Thr	GGG Gly	AGC Ser	AAA Lys	CAG Gln	CGC Arg	AGC Ser	CAG Gln	AAC Asn	CGC Arg	TCC Ser	AAG Lys	ACG Thr	CCC Pro	969
				295					300					305			
25	AAG Lys	AAC Asn	CAG Gln	GAA Glu	GCC Ala	CTG Leu	CGG Arg	ATG Met	GCC Ala	AAC Asn	GTG Val	GCA Ala	GAG Glu	AAC Asn	AGC Ser	AGC Ser	1017
			310					315					320				
	AGC Ser	GAC Asp	CAG Gln	AGG Arg	CAG Gln	GCC Ala	TGT Cys	AAG Lys	AAG Lys	CAC His	GAG Glu	CTG Leu	TAT Tyr	GTC Val	AGC Ser	TTC Phe	1065
		325					330					335					
30	CGA Arg	GAC Asp	CTG Leu	GGC Gly	TGG Trp	CAG Gln	GAC Asp	TGG Trp	ATC Ile	ATC Ile	GCG Ala	CCT Pro	GAA Glu	GGC Gly	TAC Tyr	GCC Ala	1113
	340					345					350					355	
35	GCC Ala	TAC Tyr	TAC Tyr	TGT Cys	GAG Glu	GGG Gly	GAG Glu	TGT Cys	GCC Ala	TTC Phe	CCT Pro	CTG Leu	AAC Asn	TCC Ser	TAC Tyr	ATG Met	1161
				360					365						370		
	AAC Asn	GCC Ala	ACC Thr	AAC Asn	CAC His	GCC Ala	ATC Ile	GTG Val	CAG Gln	ACG Thr	CTG Leu	GTC Val	CAC His	TTC Phe	ATC Ile	AAC Asn	1209
				375					380					385			
40	CCG Pro	GAA Glu	ACG Thr	GTG Val	CCC Pro	AAG Lys	CCC Pro	TGC Cys	TGT Cys	GCG Ala	CCC Pro	ACG Thr	CAG Gln	CTC Leu	AAT Asn	GCC Ala	1257

	390	395	400	
	ATC TCC GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC CTG AAG AAA			1305
	Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys			
	405	410	415	
05	TAC AGA AAC ATG GTG GTC CGG GCC TGT GGC TGC CAC TAGCTCCTCC			1351
	Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His			
	420	425	430	
	GAGAATTCAG ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG CCTTGGCCAG			1411
	GAACCAGCAG ACCAACTGCC TTTTGTGAGA CCTTCCCCTC CCTATCCCCA ACTTTAAAGG			1471
10	TGTGAGAGTA TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT CAGTGGCAGC			1531
	ATCCAATGAA CAAGATCCTA CAAGCTGTGC AGGCAAAACC TAGCAGGAAA AAAAAACAAC			1591
	GCATAAAGAA AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA TGCACGGACT			1651
	CGTTTCCAGA GGTAATTATG AGCGCTACC AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG			1711
	GGCGTGGCAA GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC CCGGAAGTTC			1771
15	CTGTAATAAA TGTCACAATA AAACGAATGA ATGAAAAAAAA AAAAAAAAAA A			1822

(2) INFORMATION FOR SEQ ID NO:4:

	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 431 amino acids
20	(B) TYPE: amino acid
	(D) TOPOLOGY: linear
	(ii) MOLECULE TYPE: protein
	(ix) FEATURE:
	(D) OTHER INFORMATION: /Product="hOP1-PP"
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
25	Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala
	1 5 10 15
	Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser
	20 25 30
30	Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser
	35 40 45
	Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
	50 55 60

	Pro	His	Arg	Pro	Arg	Pro	His	Leu	Gln	Gly	Lys	His	Asn	Ser	Ala	Pro	
	65					70					75					80	
	Met	Phe	Met	Leu	Asp	Leu	Tyr	Asn	Ala	Met	Ala	Val	Glu	Glu	Gly	Gly	
					85					90					95		
05	Gly	Pro	Gly	Gly	Gln	Gly	Phe	Ser	Tyr	Pro	Tyr	Lys	Ala	Val	Phe	Ser	
				100					105					110			
	Thr	Gln	Gly	Pro	Pro	Leu	Ala	Ser	Leu	Gln	Asp	Ser	His	Phe	Leu	Thr	
			115					120					125				
10	Asp	Ala	Asp	Met	Val	Met	Ser	Phe	Val	Asn	Leu	Val	Glu	His	Asp	Lys	
		130					135					140					
	Glu	Phe	Phe	His	Pro	Arg	Tyr	His	His	Arg	Glu	Phe	Arg	Phe	Asp	Leu	
	145					150					155					160	
	Ser	Lys	Ile	Pro	Glu	Gly	Glu	Ala	Val	Thr	Ala	Ala	Glu	Phe	Arg	Ile	
					165					170					175		
15	Tyr	Lys	Asp	Tyr	Ile	Arg	Glu	Arg	Phe	Asp	Asn	Glu	Thr	Phe	Arg	Ile	
			180						185					190			
	Ser	Val	Tyr	Gln	Val	Leu	Gln	Glu	His	Leu	Gly	Arg	Glu	Ser	Asp	Leu	
			195				200						205				
20	Phe	Leu	Leu	Asp	Ser	Arg	Thr	Leu	Trp	Ala	Ser	Glu	Glu	Gly	Trp	Leu	
	210						215					220					
	Val	Phe	Asp	Ile	Thr	Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg	
	225					230					235					240	
	His	Asn	Leu	Gly	Leu	Gln	Leu	Ser	Val	Glu	Thr	Leu	Asp	Gly	Gln	Ser	
					245					250					255		
25	Ile	Asn	Pro	Lys	Leu	Ala	Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn	
				260				265						270			
	Lys	Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	Glu	Val	His	Phe	
			275					280					285				
30	Arg	Ser	Ile	Arg	Ser	Thr	Gly	Ser	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser	
		290					295					300					
	Lys	Thr	Pro	Lys	Asn	Gln	Glu	Ala	Leu	Arg	Met	Ala	Asn	Val	Ala	Glu	
	305					310					315					320	
	Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	
					325					330					335		
35	Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu	
				340					345					350			

	Gly	Tyr	Ala	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro	Leu	Asn
			355					360					365			
	Ser	Tyr	Met	Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu	Val	His
		370					375					380				
05	Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
	385					390					395					400
	Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile
					405					410					415	
10	Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly	Cys	His	
				420					425					430		

What is claimed is:

1. A polypeptide chain comprising an amino acid sequence described by residues 334-430 of Seq. ID No. 1.
- 05 2. The polypeptide chain of claim 1 comprising an amino acid sequence described by residues 329-430 of Seq. ID No. 1.
3. The polypeptide chain of claim 2 comprising an amino acid sequence described by residues 292-430 of Seq. ID No. 1.
- 10 4. The polypeptide chain of claim 3 comprising an amino acid sequence described by residues 1-430 of Seq. ID No. 1.
- 15 5. A polypeptide chain useful as a subunit of a dimeric osteogenic protein, said protein being capable of inducing endochondral bone formation when implanted in a mammal in association with a matrix;

said polypeptide chain comprising an amino
20 acid sequence described by residues 334-430 of Seq. ID No. 1, including allelic variants thereof.
- 25 6. The polypeptide chain of claim 5 wherein said polypeptide chain comprises the amino acid sequence described by residues 292-430 of Seq. ID No. 1, including allelic variants thereof.:

7. The polypeptide chain of claim 1 or 5 produced by expression of recombinant DNA in a host cell.
- 05 8. The polypeptide chain of claim 7 wherein said host cell is a eucaryotic host cell.
9. The polypeptide chain of claim 8 wherein said eucaryotic host cell is a mammalian cell.
- 10 10. The polypeptide chain of claim 7 wherein said host cell is a procaryotic host cell.
11. The polypeptide chain of claim 10 wherein said procaryotic host cell is E.coli.
12. The polypeptide chain of claim 1 or 5 that is glycosylated.
- 15 13. A nucleic acid encoding the polypeptide chain of claim 1 or 5.
14. An osteogenic protein capable of inducing endochondral bone formation when implanted in a mammal in association with a matrix; said protein comprising a dimeric species having
20 two oxidized subunits, the amino acid sequence of each said subunit comprising the amino acid sequence described by residues 334-430 of Seq. ID No.1, including allelic variants thereof.
- 25 15. The osteogenic protein of claim 14 wherein said amino acid sequence comprises the sequence described by residues 292-430 of Seq. ID No. 1, including allelic variants thereof.

16. An antibody capable of binding to an epitope on a protein comprising the amino acid sequence described by residues 334-430 of Seq. ID No. 1, including allelic variants thereof.

1/3

hOP-1	Ser	Thr	Gly	Ser	Lys	Gln	Arg	Ser	Gln
mOP-1	Gly		
	1				5				
hOP-1	Asn	Arg	Ser	Lys	Thr	Pro	Lys	Asn	Gln
mOP-1
	10					15			
hOP-1	Glu	Ala	Leu	Arg	Met	Ala	Asn	Val	Ala
mOP-1	Ser
		20					25		
hOP-1	Glu	Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln
mOP-1
			30					35	
hOP-1	Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val
mOP-1
				40					45
hOP-1	Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp
mOP-1
					50				
hOP-1	Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala
mOP-1
	55					60			

FIG. 1.1

2/3

hOP-1	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala
mOP-1
			65					70	

hOP-1	Phe	Pro	Leu	Asn	Ser	Tyr	Met	Asn	Ala
mOP-1
			75					80	

hOP-1	Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu
mOP-1
				85					90

hOP-1	Val	His	Phe	Ile	Asn	Pro	Glu	Thr	Val
mOP-1	Asp
					95				

hOP-1	Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
mOP-1
	100					105			

hOP-1	Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe
mOP-1
		110					115		

hOP-1	Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys
mOP-1	Asp
			120					125	

FIG. 1.2

9/3


hOP-1	Lys	Tyr	Arg	Asn	Met	Val	Val	Arg
mOP-1
				130				135

hOP-1	Ala	Cys	Gly	Cys	His
mOP-1

FIG. 1.3

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 91/07654

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: C 07 K 15/06, C 12 N 15/12, A 61 K 37/02		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 07 K; C 12 N; A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	EP, A2, 0416578 (TAKEDA CHEMICAL INDUSTRIES, LTD. ET AL) 13 March 1991, see e.g. fig. 2, fig. 4-3 --	1-3,5- 16
P,X	Proc. Natl. Acad. Sci. USA, vol. 87, December 1990, A.J. Celeste et al: "Identification of transforming growth factor Beta family members present in bone-inductive protein purified from bovine bone ", see page 9843 - page 9847 see fig.1 --	1-16
X	WO, A1, 9011366 (GENETICS INSTITUTE, INC.) 4 October 1990, see especially table V --	1-16
<p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
20th February 1992	11. 03. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE		

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	WO, A1, 9003733 (INTERNATIONAL GENETIC ENGINEERING, INC.) 19 April 1990, see the whole document --	1-16
X	WO, A1, 8909787 (CREATIVE BIOMOLECULES, INC.) 19 October 1989, see especially claim 23 --	1-2,5,7-14,16
X	Chemical Abstracts, volume 113, no. 19, 5 November 1990, (Columbus, Ohio, US), Ozkaynak Engin et al: "OP-1 cDNA encodes an osteogenic protein in the TGF-beta family", see page 181, abstract 166493q, & EMBO J. 1990, 9(7), 2085-2093 -- -----	1-16

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/US 91/07654**

SA 53533

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 30/12/91. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0416578	13/03/91	NONE	
WO-A1- 9011366	04/10/90	AU-D- 5357790 EP-A- 0429570	22/10/90 05/06/91
WO-A1- 9003733	19/04/90	AU-B- 615810 AU-D- 4488689 CA-A- 2000498 EP-A- 0394418	10/10/91 01/05/90 11/04/90 31/10/90
WO-A1- 8909787	19/10/89	AU-D- 3444989 AU-D- 3530589 EP-A- 0362367 EP-A- 0372031 JP-T- 3500655 JP-T- 3502579 US-A- 4968590 WO-A- 89/09788 US-A- 5011691 AU-D- 5174790 EP-A- 0411105 JP-T- 3504736 US-A- 4975526 WO-A- 90/10018	03/11/89 03/11/89 11/04/90 13/06/90 14/02/91 13/06/91 06/11/90 19/10/89 30/04/91 26/09/90 06/02/91 17/10/91 04/12/90 07/09/90

For more details about this annex : see Official Journal of the European patent Office, No. 12/82